Ubs Asset Management Americas Inc Krystal Biotech, Inc. Transaction History

Ubs Asset Management Americas Inc

$446 Billion
Q3 2025

A detailed history of Ubs Asset Management Americas Inc transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 202,589 shares of KRYS stock, worth $41.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

202,589

Previous 234,320 13.54%

Holding current value

$41.8 Million

Previous $32.2 Million 11.03%

% of portfolio

0.01%

Previous 0.01%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$134.94 - $176.75 $4.28 Million - $5.61 Million	-31,731 Reduced 13.54%	202,589 $35.8 Million
Q2 2025 Aug 14, 2025	SELL	$123.36 - $181.0 $42.1 Million - $61.8 Million	-341,186 Reduced 59.28%	234,320 $32.2 Million
Q1 2025 May 19, 2025	BUY	$142.64 - $194.44 $52.1 Million - $71 Million	365,304 Added 173.79%	575,506 $104 Million
Q4 2024 Feb 14, 2025	SELL	$156.64 - $199.61 $2.31 Million - $2.94 Million	-14,743 Reduced 6.55%	210,202 $32.9 Million
Q3 2024 Nov 14, 2024	SELL	$174.7 - $213.66 $4.68 Million - $5.73 Million	-26,817 Reduced 10.65%	224,945 $40.9 Million

Q2 2024 Aug 13, 2024	BUY	$153.12 - $183.64 $35.8 Million - $42.9 Million	233,501 Added 1278.69%	251,762 $46.2 Million
Q1 2024 May 15, 2024	SELL	$108.01 - $179.35 $233,841 - $388,292	-2,165 Reduced 10.6%	18,261 $3.25 Million
Q3 2023 Nov 13, 2023	BUY	$108.51 - $130.22 $394,216 - $473,089	3,633 Added 21.63%	20,426 $2.37 Million
Q1 2023 May 15, 2023	BUY	$72.39 - $84.27 $95,699 - $111,404	1,322 Added 8.55%	16,793 $1.34 Million
Q4 2022 Feb 14, 2023	SELL	$63.14 - $79.9 $44,261 - $56,009	-701 Reduced 4.33%	15,471 $1.23 Million
Q3 2022 Nov 14, 2022	BUY	$64.85 - $82.4 $62,580 - $79,516	965 Added 6.35%	16,172 $1.13 Million
Q1 2022 May 16, 2022	BUY	$51.99 - $72.11 $260,677 - $361,559	5,014 Added 49.19%	15,207 $1.01 Million
Q4 2021 Feb 14, 2022	BUY	$39.81 - $88.24 $59,237 - $131,301	1,488 Added 17.09%	10,193 $713,000
Q2 2021 Aug 16, 2021	SELL	$62.14 - $81.82 $41,136 - $54,164	-662 Reduced 7.07%	8,705 $591,000
Q1 2021 May 14, 2021	SELL	$59.42 - $85.46 $77,246 - $111,097	-1,300 Reduced 12.19%	9,367 $721,000
Q3 2020 Nov 13, 2020	BUY	$37.76 - $48.49 $198,881 - $255,396	5,267 Added 97.54%	10,667 $459,000
Q2 2020 Aug 14, 2020	SELL	$37.03 - $60.0 $17,293 - $28,020	-467 Reduced 7.96%	5,400 $223,000
Q1 2020 May 15, 2020	BUY	$35.02 - $65.64 $61,880 - $115,985	1,767 Added 43.1%	5,867 $253,000
Q4 2019 Feb 14, 2020	BUY	$33.17 - $65.23 $135,997 - $267,443	4,100 New	4,100 $227,000

Others Institutions Holding KRYS

# of Institutions

325

Shares Held

25M

Call Options Held

241K

Put Options Held

625K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $5.29B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Krystal Biotech, Inc. Transaction History